Toll-like Receptors and Respiratory Microbiota Interactions in Idiopathic Pulmonary
Toll-like Receptors and Respiratory Microbiota Interactions in Idiopathic Pulmonary
批准号:
10322442
负责人:
David Noel O'Dwyer
金额:
$24.9万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-01-01 至 2022-12-31
关键词:
AffectAnimal Disease ModelsAnimal ExperimentationAnimal ModelAnimalsAntibioticsAreaBacteriaBioinformaticsBiological Response ModifiersBleomycinBronchoalveolar Lavage FluidCellsCellular biologyCessation of lifeClinicalCommunitiesCulture-independent methodsDataDevelopmentDevelopment PlansDiseaseDisease ProgressionEcologyEtiologyFibrosisFirmicutesFunctional disorderFutureGene ExpressionGerm-FreeGnotobioticGoalsGram-Negative BacteriaHeterogeneityHost DefenseHumanImmuneImmunologyInflammationInflammatoryInnate Immune ResponseInternal MedicineInterstitial Lung DiseasesKnowledgeLaboratoriesLeadLigandsLungLung diseasesMeasuresMentorsMichiganMicrobeMicrobiologyModelingMusNational Heart, Lung, and Blood InstituteOrganOrganismOutcomePathogenesisPatientsPersonsPhasePhysiciansPlayPrevalenceProgressive DiseaseProteobacteriaPublishingPulmonary FibrosisPulmonologyReceptor ActivationReceptor CellReceptor SignalingRecommendationReportingResearchRoleScientistSeriesStrategic PlanningTLR2 geneTLR4 geneTechniquesTherapeuticToll-like receptorsTrainingUnited StatesUniversitiesWild Type Mousebasecareer developmentdefense responsedesigndysbiosisexperienceexperimental studyfibrogenesisglobal healthhost microbiomehost microbiotaidiopathic pulmonary fibrosisimprovedindium-bleomycinlung microbiotamedical schoolsmembermicrobialmicrobiomemicrobiotamortalitymouse toll-like receptor 2novelnovel therapeutic interventionrespiratoryrespiratory microbiomerespiratory microbiotaresponseskillswound healing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Toll-like receptor and respiratory microbiota interactions in pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a lethal disease with no known cure, unknown etiology and poorly
understood pathogenesis. It is an emerging global health issue with an estimated 5 million people affected
worldwide and 17,000 deaths in the United States annually. The advent of culture-independent microbial
identification techniques has identified a respiratory microbiome associated with several lung diseases. Novel
clinical observations using bronchoalveolar lavage (BAL) fluid from IPF patients support a role for the
respiratory microbiome, both changes in community members and overall burden (dysbiosis) in disease
progression and mortality. Innate immune mediators including Toll-like receptors (TLR) have reported
associations with clinical outcomes in IPF, highlighting the previously underappreciated role of host defense in
IPF pathogenesis. However, the precise role of the respiratory microbiome and host interaction in pulmonary
fibrosis is poorly understood. The central hypothesis of this project is that dysbiosis promotes progressive lung
fibrosis through stimulation of TLRs to modulate cell-specific fibrotic responses. The specific objective is to
employ techniques from microbial ecology, bioinformatics, cell biology and animal modeling (including germ
free and gnotobiotic models) to determine the role of dysbiosis in regulating lung pathophysiology in pulmonary
fibrosis. The long term goal is to understand the role of host-microbiota interactions in the pathogenesis of IPF
and design specific therapeutic strategies for patients based on an improved understanding. In order to
achieve this objective, established animal models of pulmonary fibrosis in germ free and conventional mice
with or without antibiotic manipulation of the microbiota will be studied initially to understand the role of
dysbiosis, the host innate immune and defense response and to identify microbes associated with
experimental pulmonary fibrosis to guide gnotobiotic studies. Subsequent studies of experimental fibrosis in
animal models deficient in TLRs associated with the recognition of Gram positive (Toll-like receptor 2) and
Gram negative bacteria (Toll-like receptor 4) will further define microbiota-host interactions. Dr. O’Dwyer has
experience in TLR signaling and fibrosis and has previously published in this area. His career development
plan is focused on further mentored training in animal modeling and the bioinformatics of microbial ecology.
This project will be undertaken within the University of Michigan’s Medical School through the Department of
Internal Medicine, Department of Microbiology and Immunology and the University’s Host Microbiome Initiative.
These state-of-the-art studies will identify candidate organisms associated with fibrosis, characterize
microbiota-host (TLR) interactions that drive fibrogenesis and will highlight the crucial role that dysbiosis plays
in the pathogenesis of lung fibrosis to advance our understanding of disease etiology, refine current animal
models and inform new therapeutic strategies for this devastating lung disorder.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.matbio.2018.04.003
发表时间:
2018-04
期刊:
Matrix biology : journal of the International Society for Matrix Biology
影响因子:
--
作者:
[D. O’Dwyer;S. Gurczynski;B. Moore]
通讯作者:
D. O’Dwyer;S. Gurczynski;B. Moore
Gut Microbiota and Host Regulatory Cross-Talk in Pulmonary Fibrosis
-
批准号:10414838
-
项目类别:
-
资助金额:$51.09万
-
财政年份:2022
-
负责人:David Noel O'Dwyer
-
依托单位:
Gut Microbiota and Host Regulatory Cross-Talk in Pulmonary Fibrosis
-
批准号:10684165
-
项目类别:
-
资助金额:$50.14万
-
财政年份:2022
-
负责人:David Noel O'Dwyer
-
依托单位:
Gut Microbiota and Host Regulatory Cross-Talk in Pulmonary Fibrosis
-
批准号:10294291
-
项目类别:
-
资助金额:$47.7万
-
财政年份:2021
-
负责人:David Noel O'Dwyer
-
依托单位:
Toll-like Receptors and Respiratory Microbiota Interactions in Idiopathic Pulmonary
-
批准号:10080752
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2018
-
负责人:David Noel O'Dwyer
-
依托单位:
海外基金